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Abstract
Background: Breast cancer is one of the most common malignancies with increasing incidences every year and a
leading cause of death among women. Although early stage breast cancer can be effectively treated, there are
limited numbers of treatment options available for patients with advanced and metastatic disease. The novel breast
cancer associated antigen NY-BR-1 was identified by SEREX analysis and is expressed in the majority (>70%) of
breast tumors as well as metastases, in normal breast tissue, in testis and occasionally in prostate tissue. The
biological function and regulation of NY-BR-1 is up to date unknown.
Methods: We performed an in silico analysis on the genetic variations of the NY-BR-1 gene using data available in
public SNP databases and the tools SIFT, Polyphen and Provean to find possible functional SNPs. Additionally, we
considered the allele frequency of the found damaging SNPs and also analyzed data from an in-house sequencing
project of 55 breast cancer samples for recurring SNPs, recorded in dbSNP.
Results: Over 2800 SNPs are recorded in the dbSNP and NHLBI ESP databases for the NY-BR-1 gene. Of these, 65
(2.07%) are synonymous SNPs, 191 (6.09%) are non-synoymous SNPs, and 2430 (77.48%) are noncoding intronic
SNPs. As a result, 69 non-synoymous SNPs were predicted to be damaging by at least two, and 16 SNPs were
predicted as damaging by all three of the used tools. The SNPs rs200639888, rs367841401 and rs377750885 were
categorized as highly damaging by all three tools. Eight damaging SNPs are located in the ankyrin repeat domain
(ANK), a domain known for its frequent involvement in protein-protein interactions. No distinctive features could
be observed in the allele frequency of the analyzed SNPs.
Conclusion: Considering these results we expect to gain more insights into the variations of the NY-BR-1 gene and
their possible impact on giving rise to splice variants and therefore influence the function of NY-BR-1 in healthy tissue
as well as in breast cancer.
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Background
Breast cancer is one of the most common malignancies
and a leading cause of death among women. Although
early stage breast cancer can be effectively treated, there
are limited numbers of treatment options available for
patients with advanced and metastatic disease. Therefore
new targets and strategies need to be developed. A novel
breast cancer differentiation antigen, designated as New
York-Breast-1 (NY-BR-1), was identified by a serological
cloning strategy (SEREX) [1, 2] and could be a possible
target for immunotherapy for breast cancer patients [3].
NY-BR-1, also known as ANKRD30A, is located on
chromosome 10p11-p12. There are several transcripts
existing, which contain between 36 and 42 exons. Al-
though computational analyses have identified NY-BR-1
as being a potential transcription factor, the functional
aspects of this 158.9 kDa protein are still unknown. NY-
BR-1 protein was shown to be expressed in normal
breast epithelia cells and in a majority of primary breast
cancers [4, 5], while NY-BR-1 mRNA was detected
predominantly in breast cancers [6, 7]. NY-BR-1 is over-
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expressed in over 70% of primary breast tumors and me-
tastases [1] and additional details on the involvement of
NY-BR-1 in breast cancer will lead to a better under-
standing of the underlying processes.
Genetic variation can have a major impact on gene
function and the functional range of a gene cannot be
fully understood without awareness of the potential
variability within a gene [8]. To further understand the
biological function and regulation of NY-BR-1 and
its potential for therapeutic approaches, we per-
formed an in silico analysis on the genetic variations
of the NY-BR-1 gene.
Human genetic variants may occur in diverse nucleotide
compositions, including single nucleotide polymorphisms
(SNPs) and structural variants such as small insertions
and deletions (indels) or large copy number variations.
Among these, SNPs are the most prevalent form of
human variation and it has been estimated that one SNP
exists every 290 base-pairs in the human genome [9]. Evi-
dences show that through SNPs a wide range of human
diseases such as cancer or autoimmunity can be triggered
[10, 11]. SNPs also might affect the pharmacokinetics and
pharmacodynamics of certain drugs in cancer therapy
[12]. The transcriptional regulation of a protein, its struc-
ture and its function can be affected by a single base
substitution, deletion or insertion. Two groups of SNPs
are known: synonymous (sSNP) and non- synonymous
SNPs (nsSNP). The latter results in changes of the trans-
lated amino acid sequence.
A number of studies have shown associations between
one or few SNPs and complex diseases, but until today
it is not entirely clear how much impact SNPs have on
certain traits in different populations.With the steadily
increasing number of known human nsSNPs, there is
also growing interest in identification of the subset that
may affect protein function. Various types of features
can be used to predict the functional impact of nsSNPs:
physical and chemical properties of the affected amino
acids, structural properties of the encoded protein, and
evolutionary properties, which can be inferred from
sequence alignments of homologous proteins [13]. SIFT
(Sorting Intolerant from Tolerant) [14], PROVEAN
(Protein Variation Effect Analyzer) [15] and PolyPhen-2
(Polymorphism Phenotyping v2) [16] are computational
prediction methods which take several of these proper-
ties into account and calculate a score to predict
whether a given nsSNP has a functional impact. We ob-
tained all SNPs for the NY-BR-1 gene and investigated
the nsSNPs for their functional impact by using these
three prediction tools. We identified a small number of
nsSNPs which seem to affect the protein function of
NY-BR-1. Additionally, we used in house sequencing
data to analyze whether certain SNPs are enriched in
breast cancer patients.
Methods
SNP Mining
dbSNP is hosted by the National Center for Biotechnology
Information (NCBI) and is the largest repository of SNP
data with over 140 million submitted variations [17].
Another source of variation data is provided by the
“The National Heart, Lung and Blood Institute” (NHLBI).
With the aim of discovering novel genes and mechanisms
contributing to heart, lung and blood disorders, the
NHLBI started the Exome Sequencing Project (ESP) and a
large and well-phenotyped population with over 200,000
individuals was assembled. The protein coding regions of
each individual genome (i.e. exome) is sequenced and the
variation data is made publicly available [18].
The Ensembl Variation database incorporates vari-
ation data from several sources including dbSNP and
NHLBI ESP. We used the web interface MartWizard
(http://www.biomart.org/) of the BioMart Central Portal
which offers access and crosslinks a wide array of bio-
logical databases.
The Ensembl transcript ID ENST00000611781 of the
ANKRD30A gene was used to retrieve all available
germline variations together with the corresponding
genomic coordinates, the variant descriptions, the val-
idation status, and allele frequency. Using the variant
descriptions, we filtered coding non-synonymous SNPs
(nsSNPs), coding synonymous SNPs (sSNPs) and in-
tronic SNPs.
Additionally, exome-sequencing data were provided of
55 breast cancer patients from an in-house sequencing
project (Division of Molecular Genetics, German Cancer
Research Center (DKFZ), Heidelberg, Germany, and
Heidelberg Center for Personalized Oncology (HIPO)).
We also analyzed this dataset and looked for SNPs
which are recorded in dbSNP.
Prediction of the functional impact of coding nsSNPs
using SIFT
The prediction tool SIFT evaluates the functional impact
of SNPs based on sequence homology. The prediction is
based on the degree of conservation of each amino acid
residue of the query sequence. To assess the degree of
conservation, SIFT compiles a dataset of functionally
related protein sequences by searching the protein data-
bases UniProt and TrEMBL using the PSI-BLAST algo-
rithm and builds an alignment of the found sequences
and the query sequence. In the second step a normalized
probability for each substitution at each position of the
alignment is calculated and is then recorded in a scaled
probability matrix. This scaled probability is also called
the SIFT score and a substitution is considered to be tol-
erated if the score is greater than 0.05; those less than
0.05 are predicted to be deleterious. The SIFT approach
assumes that a highly conserved position is intolerant to
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most substitutions, whereas a poorly conserved position
can tolerate most substitutions.
Prediction of the functional impact of coding nsSNPs
using PROVEAN
The tool PROVEAN also uses an alignment approach to
assesses the functional impact of SNPs. PROVEAN con-
sists of two main steps. In the first step, a set of homolo-
gous and distantly related sequences from the NCBI NR
protein database is collected using BLASTP. To remove
redundancy, the collected sequences are clustered, based
on a sequence identity of 80%. A so called supporting
set of sequences is assembled by adding sequences from
clusters most similar to the query sequence, until a suffi-
cient number of clusters is reached in the supporting
set. In the second step, for each sequence in the sup-
porting sequence set, a delta score is computed using
the BLOSUM62 substitution matrix. For each cluster, an
average delta score is computed, and the averaged delta
scores are again averaged among all clusters. This un-
biased averaged delta score is the final PROVEAN score.
The PROVEAN approach assumes that a variation,
which reduces similarity of protein A to the homologous
or distantly related protein B, is more likely to cause a
damaging effect. Thus, the impact of a variation on pro-
tein function can be measured as the change in align-
ment score, the delta score. Low delta scores are
interpreted as variations leading to a deleterious effect
on protein function, while high delta scores are inter-
preted as variations with neutral effect.
The tools SIFT and PROVEAN are available online at
http://sift.jcvi.org/ and http://provean.jcvi.org/, respectively.
On the website, we used the tool PROVEAN Human
Genome Variants, which provides PROVEAN and SIFT
predictions for a list of human genome variants. We sub-
mitted the list of genomic coordinates and variants of our
filtered 191 nsSNPs, and chose the default threshold of
delta score < = −2.5 to detect deleterious variations.
Prediction of the functional impact of coding nsSNPs
using PolyPhen-2
PolyPhen-2 combines information on sequence features,
multiple alignments with homologous proteins, and
structural parameters to predict the impact of a SNP on
protein function.
For sequence-based assessment, PolyPhen-2 tries to
identify the query as an entry in the UniProtKB/Swiss-
Prot database. Using the feature table of the correspond-
ing entry, PolyPhen-2 checks if a given SNP occurs at
functional relevant site, e.g. if the SNP lies within a
transmembrane, signal peptide, or binding region.
Similar to SIFT, PolyPhen-2 also assesses the degree of
conversation of the position where the SNP occurs by
utilizing a multiple sequence alignment of homologous
sequences. For each variant PolyPhen-2 calculates a
position-specific independent counts (PSIC) score. The
PSIC score difference between the two variants describes
the impact of a particular amino acid substitution: the
higher the PSIC score difference, the higher functional
impact the substitution is likely to have.
A BLAST query of the query sequence against protein
structure databases is carried out to identify correspond-
ing 3D protein structures. If corresponding structures
are found, they are used to assess, whether the SNP is
likely to destroy the hydrophobic core, interactions with
ligands or other important features of the protein.
Finally, all parameters are taken together and empirical
prediction rules are applied to make the final decision,
whether the SNP is damaging or benign.
PolyPhen-2 is available online at http://genetics.bwh.-
harvard.edu/pph2/. We used the option ‘Batch query’
and submitted the list of genomic coordinates and vari-
ants of our filtered 191 nsSNPs.
DNA Sequencing and Analysis
The exon-sequencing library was prepared according to
Agilent SureSelect Human All Exon V5 + UTRs proto-
col. Paired-end sequencing (2*101 bp) was carried out
with Illumina Hiseq-2000 instruments. Paired-end
sequencing reads were mapped to human genome refer-
ence assembly (hg19) with Burrows-Wheeler Aligner
(BWA-v0.6.2) [19]. SAMtools mpileup (version-0.1.19)
and bcftools (version-0.1.19) [20] were used to detect
SNVs. Additional filtering step to remove possible arte-
facts was previously described [21]. Alignments on the
NY-BR-1 gene only were extracted for this study and
SNP states called at respective positions.
Results
SNP Mining
In the Ensembl BioMart database 2898 SNPs are recorded
for the ANKRD30A transcript ENST00000611781. 2880
of these were imported from dbSNP and 18 from NHLBI
ESP. 1832 SNPs have been validated by independent
submissions or frequency/genotype data. However, the
clinical significance has not been determined yet for any
of the SNPs.
Out of all 2898 SNPs, 65 (2.07%) were sSNPs, 191
(6.09%) were nsSNPs, and 2430 (77.48%) occurred in in-
tronic regions (Fig. 1). 40 of the downloaded SNPs are
annotated as splice region variants in dbSNP. We
selected nsSNPs for our investigation.
Deleterious nsSNPs predicted by SIFT
Among the 191 analyzed nsSNPs, 79 nsSNPs were
identified to be damaging with a tolerance index
score > = 0.5. Ten nsSNPS showed a highly damaging
tolerance index score of 0.00, namely rs200639888,
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rs372199195, rs144539033, rs369532435, rs199571878,
rs376821949, rs267602482, rs201234943, rs367841401,
and rs377750885. Nine nsSNPs had a tolerance index
score of 0.001, nine nsSNPs had a score of 0.002, and five
had a score of 0.003. The remaining nsSNPs contained
tolerance index scores varying between 0.004 and 0.048.
Damaging nsSNPs predicted by PROVEAN
28 nsSNPs out of the analyzed 191 nsSNPs were
predicted to be deleterious with a delta score of < = −2.5.
10 nsSNPs showed a highly deleterious score of < − 4.00:
rs200639888 (−5.962), rs61737412(−5.030), rs201943652
(−4.758), rs189195791(−6.263), rs367841401 (−4.465),
Fig. 1 Graphical representation of distribution of intronic SNPs, non-synoymous SNPs (nsSNPs), synonymous SNPs (sSNPs), and SNPs at splicing
sites for the NY-BR-1 gene, based on the dbSNP and NHLBI ESP databases
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rs185294248(−4.366), rs374753521 (−4.184), rs371981
371 (−4.603), rs377750885(−5.87), and rs201764363
(−4.025).
20 nsSNPs were predicted as damaging variations by
SIFT and PROVEAN. rs200639888, rs367841401, and
rs377750885 were predicted to be highly damaging by
SIFT with a tolerance index score of 0.00 and are also pre-
dicted to be highly deleterious by PROVEAN with delta
scores of −5.962 and −4.465, and −5.87 respectively.
Damaging nsSNPs predicted by PolyPhen
Out of the 171 nsSNPs submitted to the PolyPhen-2
server, 102 nsSNPs were considered to be damaging: 44
nsSNPs were predicted to be ‘probably damaging’ with
an PSIC score of 2.00 or more, and 58 nsSNPs were pre-
dicted to be ‘possibly damaging’ with an PSIC score of
1.40-1.90. The remaining 89 nsSNPs were predicted to
be benign.
Sixty-four of the nsSNPs which were predicted to be
damaging by SIFT, were also predicted damaging by
PolyPhen. rs200639888, rs369532435, rs267602482,
rs201234943, and rs377750885 were among the nsSNPs
predicted to be highly damaging by SIFT with a toler-
ance index score of 0.00. These five nsSNPs also have
high PSIC scores predicted by PolyPhen (2.439, 2.746,
2.23, 2.373, and 2.46 respectively).
19 nsSNPs were predicted to be damaging by Provean
and PolyPhen, and 16 nsSNPs were predicted to be dam-
aging by all three of the used tools (Fig. 2). The nsSNPs
rs200639888, rs367841401, and rs377750885 were pre-
dicted to be highly damaging/deleterious by all three
tools.
Damaging nsSNPs predicted by at least two tools
As summarized in Table 1, 16 nsSNPs were predicted
damaging/deleterious by all three tools, and a total of 69
nsSNPs were predicted damaging by at least two of the
used tools. We selected these 69 nsSNPs to perform a
more detailed analysis.
Analysis of the spectrum of nsSNPs on the nucleotide
level showed a conserved profile with A > T/T > A tran-
sitions and hydrophile > hydrophile transitions being the
most frequent changes (Fig. 3a and b).
The nsSNPs rs200639888 and rs367841401, which
were predicted to be highly damaging by all three tools,
have an amino acid change from leucine to proline
which are both hydrophobe amino acids. The third dam-
aging nsSNP predicted by all three tools, rs377750885,
has a change from glutamic acid (hydrophile) to (hydro-
phobe) valine.
The minor allele frequency describes the proportion of
the least common allele in a certain population pool.
Table 1 summarizes the minor allele frequency for the
Fig. 2 Venn diagram showing the overlap of the predictions made by the three tools PolyPhen, PROVEAN and SIFT
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Table 1 Summary of all 69 nsSNPs predicted 504 to be damaging/deleterious by at least two of the used tools
SNP ID Location on
chromosome
Location in
protein
Nucleotide
variation
Protein
variation
SIFT prediction Provean
prediction
Polyphen
prediction
AA change In ANK
domain
Minor Allele
Frequency
rs113525905 37447451 613 G/A G/R Damaging(0.013) Neutral(−1.25) probably damaging(0.998) hydrophobe > hydrophile 0,19
rs1200875 37505192 985 C/T R/C Damaging(0.001) Neutral(0.32) possibly damaging(0.762) hydrophile > hydrophile 12,89
rs140013037 37505242 1001 G/C K/N Damaging(0.016) Deleterious(−3.58) probably damaging(0.963) hydrophile > hydrophile 0,17
rs144539033 37430978 385 T/C W/R Damaging(0) Neutral(−1.04) possibly damaging(0.943) hydrophobe > hydrophile 0,15
rs17590850 37470375 730 A/C N/H Damaging(0.002) Neutral(−0.35) possibly damaging(0.94) hydrophile > hydrophile NA
rs17606645 37470263 723 A/T K/N Damaging(0.004) Neutral(−0.44) possibly damaging(0.851) hydrophile > hydrophile NA
rs183760470 37451752 660 A/C K/Q Damaging(0.002) Neutral(−0.78) possibly damaging(0.851) hydrophile > hydrophile 0,01
rs184702413 37481992 838 A/G E/G Damaging(0.017) Neutral(−1.16) possibly damaging(0.851) hydrophile > hydrophobe 0,41
rs185294248 37508038 1133 T/C F/S Damaging(0.012) Deleterious(−4.37) benign(0.006) hydrophobe > hydrophile 0,11
rs190686350 37419160 122 G/A A/T Damaging(0.012) Deleterious(−3.27) probably damaging(0.997) hydrophobe > hydrophile Yes 0,01
rs199571878 37438753 541 A/C K/Q Damaging(0) Neutral(−0.47) possibly damaging(0.947) hydrophile > hydrophile 0,079
rs199691521 37488715 926 A/T E/V Damaging(0.02) Neutral(−1.16) probably damaging(0.994) hydrophile > hydrophobe NA
rs199795040 37508139 1167 C/A Q/K Damaging(0.002) Neutral(−2.3) possibly damaging(0.886) hydrophile > hydrophile NA
rs199841724 37508538 1300 C/A H/N Damaging(0.032) Deleterious(−3.11) benign(0.03) hydrophile > hydrophile NA
rs199874591 37451705 644 C/A P/H Damaging(0.001) Neutral(−1.11) probably damaging(0.997) hydrophobe > hydrophile NA
rs200114350 37486388 899 A/G N/S Damaging(0.006) Neutral(−1.64) possibly damaging(0.713) hydrophile > hydrophile NA
rs200264724 37431045 407 C/T T/M Damaging(0.001) Neutral(0.55) probably damaging(0.989) hydrophile > hydrophobe NA
rs200331751 37478422 817 G/A D/N Damaging(0.028) Neutral(−0.12) possibly damaging(0.818) hydrophile > hydrophile NA
rs200399695 37506718 1060 G/C R/T Damaging(0.029) Deleterious(−2.91) benign(0.013) hydrophile > hydrophile NA
rs200639888 37419170 125 T/C L/P Damaging(0) Deleterious(−5.96) probably damaging(0.997) hydrophobe > hydrophobe Yes NA
rs200651327 37418912 105 G/A E/K Tolerated(0.081) Deleterious(−3.37) probably damaging(0.999) hydrophile > hydrophile Yes NA
rs200845385 37430796 324 C/T T/I Damaging(0.002) Neutral(−0.78) possibly damaging(0.898) hydrophile > hydrophobe NA
rs200929491 37508788 1383 G/A R/H Damaging(0.002) Deleterious(−3.55) probably damaging(0.987) hydrophile > hydrophile NA
rs201234943 37447491 626 A/T K/M Damaging(0) Neutral(−1.29) probably damaging(0.98) hydrophile > hydrophobe 0,01
rs201628233 37478440 823 G/T A/S Damaging(0.022) Neutral(−0.44) possibly damaging(0.841) hydrophobe > hydrophile 0,39
rs201669885 37447325 602 C/G P/A Damaging(0.012) Neutral(−1.66) possibly damaging(0.924) hydrophobe > hydrophobe 0,01
rs201764363 37508814 1392 G/C A/P Damaging(0.002) Deleterious(−4.03) probably damaging(0.969) hydrophobe > hydrophobe 0,01
rs201858051 37508539 1300 A/G H/R Tolerated(0.108) Deleterious(−3.06) possibly damaging(0.651) hydrophile > hydrophile NA
rs201885728 37451744 657 T/C L/S Damaging(0.01) Neutral(−0.08) possibly damaging(0.932) hydrophobe > hydrophile 0,01
rs201943652 37421175 173 T/C L/P Damaging(0.011) Deleterious(−4.76) probably damaging(0.995) hydrophobe > hydrophobe Yes NA
rs201976592 37447446 611 C/A T/N Damaging(0.002) Neutral(−1.14) possibly damaging(0.851) hydrophile > hydrophile 0,05
rs202090351 37430699 292 C/A P/T Damaging(0.001) Neutral(−1.91) probably damaging(0.998) hydrophobe > hydrophile NA
rs202098264 37430875 350 C/G F/L Damaging(0.003) Neutral(−1.01) probably damaging(0.965) hydrophobe > hydrophobe NA
rs202200263 37454055 679 A/G D/G Damaging(0.001) Neutral(−1.04) possibly damaging(0.924) hydrophile > hydrophobe 0,01
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Table 1 Summary of all 69 nsSNPs predicted 504 to be damaging/deleterious by at least two of the used tools (Continued)
rs267602477 37419220 142 G/A A/T Damaging(0.016) Deleterious(−3.41) probably damaging(0.997) hydrophobe > hydrophile Yes NA
rs267602481 37438727 532 C/T S/F Damaging(0.001) Neutral(−1.27) possibly damaging(0.842) hydrophile > hydrophobe NA
rs267602482 37441009 556 C/T S/F Damaging(0) Neutral(−1.66) probably damaging(0.99) hydrophile > hydrophobe NA
rs267602485 37507968 1110 G/A E/K Damaging(0.021) Deleterious(−3.34) probably damaging(0.98) hydrophile > hydrophile NA
rs367841401 37508002 1121 T/C L/P Damaging(0) Deleterious(−4.47) probably damaging(0.969) hydrophobe > hydrophobe NA
rs368559588 37508121 1161 G/A A/T Damaging(0.04) Neutral(−0.75) possibly damaging(0.618) hydrophobe > hydrophile 0,05
rs368660392 37442552 587 A/G H/R Damaging(0.003) Neutral(−1.4) possibly damaging(0.932) hydrophile > hydrophile 0,01
rs369099906 37508651 1337 A/T L/F Damaging(0.001) Deleterious(−3.22) probably damaging(0.999) hydrophobe > hydrophobe NA
rs369118323 37422851 209 C/T L/F Damaging(0.01) Neutral(−1.52) probably damaging(0.993) hydrophobe > hydrophobe Yes NA
rs369532435 37438591 519 A/T K/M Damaging(0) Neutral(−1.13) probably damaging(0.996) hydrophile > hydrophobe 0,01
rs371253665 37451583 636 C/T P/L Damaging(0.001) Neutral(−0.77) probably damaging(0.994) hydrophobe > hydrophobe 0,01
rs371384886 37430859 345 C/T A/V Damaging(0.001) Neutral(−0.56) probably damaging(0.997) hydrophobe > hydrophobe 0,01
rs371443557 37431010 395 T/G I/M Damaging(0.004) Neutral(−0.28) possibly damaging(0.676) hydrophobe > hydrophobe NA
rs371878855 37508548 1303 A/G Q/R Damaging(0.012) Deleterious(−2.52) possibly damaging(0.808) hydrophile > hydrophile NA
rs371981371 37508671 1344 C/A A/D Damaging(0.003) Deleterious(−4.6) probably damaging(0.989) hydrophobe > hydrophile NA
rs372199195 37430803 326 T/G D/E Damaging(0) Neutral(−0.13) possibly damaging(0.643) hydrophile > hydrophile NA
rs372420008 37430922 366 A/G K/R Damaging(0.007) Neutral(−0.62) possibly damaging(0.956) hydrophile > hydrophile NA
rs372878721 37442530 580 G/A V/M Damaging(0.013) Neutral(−0.77) probably damaging(0.976) hydrophobe > hydrophobe NA
rs373377344 37508379 1247 G/A E/K Damaging(0.048) Deleterious(−2.78) possibly damaging(0.898) hydrophile > hydrophile NA
rs373380909 37422972 249 G/T G/V Damaging(0.003) Neutral(−2.41) probably damaging(0.999) hydrophobe > hydrophobe Yes NA
rs373997768 37505217 993 A/C K/T Damaging(0.003) Deleterious(−2.76) probably damaging(0.963) hydrophile > hydrophile NA
rs374024060 37430943 373 C/T T/M Damaging(0.011) Neutral(−0.76) probably damaging(0.975) hydrophile > hydrophobe NA
rs374037740 37441038 566 T/G W/G Damaging(0.009) Neutral(−1.82) possibly damaging(0.826) hydrophobe > hydrophobe NA
rs374739457 37454063 682 G/C E/Q Damaging(0.018) Neutral(−0.76) possibly damaging(0.851) hydrophile > hydrophile NA
rs374753521 37508446 1269 A/C Y/S Damaging(0.031) Deleterious(−4.18) benign(0.347) hydrophile > hydrophile NA
rs375945698 37505306 1023 G/C E/Q Damaging(0.018) Neutral(−2.17) probably damaging(0.999) hydrophile > hydrophile NA
rs376116213 37505157 973 G/A R/K Damaging(0.004) Neutral(−2.23) probably damaging(0.976) hydrophile > hydrophile 0,01
rs376821949 37438772 547 G/A R/K Damaging(0) Neutral(0.04) possibly damaging(0.643) hydrophile > hydrophile NA
rs377410013 37440994 551 T/C M/T Damaging(0.045) Neutral(−0.42) possibly damaging(0.717) hydrophobe > hydrophile NA
rs377740138 37430720 299 G/A V/M Damaging(0.002) Neutral(−0.39) possibly damaging(0.845) hydrophobe > hydrophobe NA
rs377744149 37508352 1238 G/A D/N Tolerated(0.083) Deleterious(−3.19) probably damaging(0.971) hydrophile > hydrophile 0,01
rs377750885 37508803 1388 A/T E/V Damaging(0) Deleterious(−5.87) probably damaging(0.997) hydrophile > hydrophobe NA
rs41276130 37451768 665 T/G L/W Damaging(0.002) Neutral(−0.98) probably damaging(0.983) hydrophobe > hydrophobe 4,17
rs45515098 37440991 550 C/T P/L Damaging(0.028) Neutral(−1.27) possibly damaging(0.581) hydrophobe > hydrophobe 0,01
rs61737412 37419218 141 C/T T/M Damaging(0.035) Deleterious(−5.03) possibly damaging(0.951) hydrophile > hydrophobe Yes 4,13
The 16 nsSNPs in bold letters were predicted damaging/deleterious by all three used tools
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69 nsSNPs, predicted to be deleterious by two tools. Al-
lele frequencies are only provided for 26 of the analyzed
SNPs. For most SNPs the minor allele frequency is
below 1% except for the SNPs rs1200875 (12.9%),
rs41276130 (4.17%), and rs61737412 (4.13%).
Clinical data analysis
As part of an in-house cancer sequencing project,
exome-sequencing data was available for 55 breast can-
cer patients and was provided for analysis in this study.
In the analyzed patient cohort 11 SNPs were detected in
in the NY-BR-1 gene: rs34042320, rs1209750, rs34552
277, rs61737412, rs41276130, rs1200876, rs1200875, rs4
1304589, rs116939015, and rs16937417 (Table 2). Seven
SNPs occur in more than 10 patients and three of these
(rs61737412, rs41276130, rs1200875) were predicted
damaging by at least two of the used tools. These SNPs
also have a high minor allele frequency of 4.13, 4.17, and
12.89, respectively. The SNP rs1209750 occurs in 49
patients, which corresponds to almost 90% of analyzed
patients. rs1209750 also has a high minor allele
frequency of 48,22%. This SNP however, was not pre-
dicted to be damaging. Likewise, the SNPs rs1200876,
rs34042320, and rs34552277 occur in a large fraction of
the patient cohort and also have a high minor allele fre-
quency. These SNPs were also not predicted to be dam-
aging. A Fisher’s exact test was performed to test the
difference in allele frequencies of the SNPs in our breast
Fig. 3 Graphical representation of spectrum of damaging nsSNPs variation. a) nucleotide variations, b) amino acid variations
Table 2 SNPs and mutations detected in the analyzed breast cancer patient cohort of 55 patients
SNP ID Prediction Frequency in Patient Cohort Minor Allele Frequency in dbSNP p-value (Fisher’s exact test)
rs116939015 1,82 0,59 0,4921
rs1200875 damaging 45,45 12,89 0,0018
rs1200876 45,45 12,77 0,0016
rs1209750 89,09 48,22 0,0149
rs12766884 1,82 4,432 0,0853
rs16937417 1,82 2,61 0,3646
rs34042320 18,18 3,27 0,0033
rs34552277 38,18 22,76 0,3381
rs41276130 damaging 21,82 4,17 0,0020
rs41304589 9,09 2,55 0,2059
rs61737412 damaging 27,27 4,13 3,80E-05
somatic (chr10:37430943:C/T) 1,82 NA
somatic (chr10:37447328:A/G) 1,82 NA
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cancer patient cohort against the dbSNP reference for
significance which showed six SNPs to be significantly
enriched in the analyzed patient cohort.
Two somatic mutations were also detected in the
patient cohort which both occur only in single patients.
The somatic mutation chr10:37430943:C > T translates
to a T >M transition at position 317 in the NY-BR-1
protein. This mutation is also documented in the Cata-
logue of Somatic Mutations in Cancer (COSMIC) [22]
database as COSM4137978 and was reported in two
patients with ovary cancer. The second somatic muta-
tion chr10:37447328:A > G translates to a N > D transi-
tion at protein position 547 and is not documented in
the COSMIC database.
Discussion
Information on genetic variation can provide a valuable
insight into the functional range and critical regions of a
gene. SNPs are the most common form of genetic varia-
tions and a link between SNPs and complex diseases
have been reported for a number of cases. The BRCA-1
gene for example and some of its interaction partners
are associated with breast cancer. SNPs in these genes
are not just involved in the onset of a disease but
they can promote also disease progression and out-
come [23, 24]. Here, we systematically analyzed SNPs
in the NY-BR-1 gene to identify those SNPs which
can modify the functional properties of the protein.
In the Ensembl BioMart database 2898 SNPs are re-
corded for the NY-BR-1 transcript ENST00000611781.
Out of these, 191 (6.01%) were nonsynonymous SNPs
(nsSNPs), i.e. polymorphisms which translate into an
altered amino acid sequence. As these types of SNPs are
most likely to have an effect on protein function, we
chose to analyze only them further.
Computational approaches use various types of fea-
tures to predict the functional impact of nsSNPs: phys-
ical and chemical properties of the affected amino acids,
structural properties of the encoded protein, and evolu-
tionary properties, which can be inferred from sequence
alignments of homologous proteins. We chose three
state-of-the-art computational tools which can predict
the effects of amino acid substitutions on protein func-
tion: SIFT, Provean and PolyPhen2.
191 nsSNPs were analyzed and the results varied
between the used tools: SIFT predicted 79 damaging
nsSNPs, Provean 28 nsSNPs, and PolyPhen2 102
nsSNPs. 16 nsSNPs were predicted damaging by all three
tools, and a total of 69 nsSNPs were predicted damaging
by at least two of the used tools. SIFT and PolyPhen2
have the biggest overlap with 63 common predictions.
This may be due to the common step of assessing the
degree of conversation by utilizing a multiple sequence
alignment of homologous sequences. 36 damaging
nsSNPs were only predicted by PolyPhen2 because Poly-
Phen2 is the only tool that takes functional relevant sites
into account. The location of the 69 damaging SNPS
within the ANKRD30A gene is shown in Fig. 4a.
Up to date the structure of NY-BR-1 has not been
solved yet and no homology models for the entire pro-
tein are available. Thus, we unfortunately could not
evaluate the location and effect of the predicted dam-
aging nsSNPs on the protein structure.
In the UniProt database six ankyrin (ANK) repeat mo-
tifs are documented for NY-BR-1. The ANK repeat motif
is one of the most common protein-protein interaction
motifs in nature and occurs in a large number of func-
tionally diverse proteins. The structure of the ANK re-
peat motif is conserved: each repeat typically consists of
30–34 amino acid residues comprising two anti-parallel
α-helices and a long loop ending in a β-hairpin [25].
Proteins containing the ANK repeat motif are involved
in a diverse set of cellular functions, and defects in ANK
repeat proteins have been associated with a number of
human diseases [26, 27]. Hence, a variation within such
a functional domain is likely to have an impact on
protein function.
Eight of the 69 damaging nsSNPs in NY-BR-1 are
located in an ANK repeat motif: rs190686350, rs20063
9888, rs61737412, rs267602477, rs201943652, rs2006
51327, rs369118323, rs373380909. PolyPhen2 predicted
all of them as damaging, whereas Provean predicted two,
and SIFT one of them as not damaging. SNPs influen-
cing the splicing process also may have an impact on
protein function if the newly generated transcripts are
translated into proteins. In dbSNP, 39 of the NY-BR-1
SNPs are annotated to be splicing, located at donor or
acceptor sites (Fig. 4b). These SNPs have the potential to
influence the splicing process and thus give rise to new
transcripts.
An unknown fraction of SNPs submitted to the public
databases may not be true polymorphisms, but examples
of sequencing errors. Therefore it is important to con-
sider the validation status of each SNP. A polymorphism
can be validated by independent submissions or fre-
quency/genotype data. In our dataset 1832 out of 2898
SNPs have been validated. Considering the 69 damaging
nsSNPs, 16 have not been validated yet. As these nsSNPs
seem to have an impact on protein function, validation
of them should especially be considered.
Allele frequencies are only provided for 26 of the ana-
lyzed SNPs 69 nsSNPs, predicted to be damaging by at
least two tools. SNPs with no information on allele fre-
quencies are usually based on single submissions, often
from sequencing projects of cancer patient cohorts and
therefore might be of special relevance. The minor allele
frequency of 16 out of 26 analyzed SNPs is below 0.1%,
for six analyzed SNPs the minor allele frequencies are
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between 0.1% and 1%, and for three SNPs the minor
allele frequency is greater than 4% According to Frazer
et al. these SNPs can be classified according to their
minor allele frequencies: variants with minor allele fre-
quencies between 0.1% and 3% were defined as rare vari-
ants, variants with minor allele frequencies of less than
0.1% as novel variants, and high-frequency common var-
iants were defined as variants with minor allele frequen-
cies greater than 5% [28].
We also analyzed in house exome-sequencing data of
55 breast cancer patients and as expected, NYBR1 was
found to be expressed in all patients (data not shown).
Somatic mutations were only detected in two patients.
Also, as indicated by the database research on COSMIC,
the two somatic mutations are not being frequently
observed in cancer patients. Only one of the mutations,
COSM4137978, is documented in COSMIC and was ob-
served in two cases of ovary cancer. Also using the
COSMIC database, we further searched for NY-BR-1
mutations in breast cancer patients. Only 27 out of 1436
breast cancer patients were found to have a somatic
mutation in NY-BR-1 indicating that somatic mutations
in this gene is not a frequent event in breast cancer
patients.
In contrast, 11 SNPs in the NY-BR-1 gene were found
in the in-house patient cohort, seven SNPs occurring in
more than 10 patients. Three of these frequent SNPs
(rs61737412, rs41276130, rs1200875) were also predicted
damaging by at least two of the used tools. These SNPs
also have a high minor allele frequency in dbSNP, they
are however highly enriched in the patient cohort (p-
value < 0.002, Fisher’s exact test). There are also three
other SNPs (rs1200876, rs1209750, rs34042320), that are
enriched in the patient cohort (p-value < 0.01, Fisher’s
exact test), but these SNPs were not predicted damaging.
These SNPs which seem to be enriched in breast cancer
patients need to be further analyzed in larger patient
cohorts to elucidate whether there is a correlation to
clinical status and outcome. The effect of these SNPs on
protein function also still needs to be determined.
Conclusion
In summary, we have identified 69 damaging nsSNPs
within the coding region of the breast cancer associated
a
b
Fig. 4 Graphical representation of location of NY-BR-1 SNPs. a) damaging SNPs, b) splicing SNP. SNPs predicted damaging by all three tools are
underlined and SNPs located in an ANK repeat domain are highlighted with a box
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NY-BR-1 gene. Moreover, we found 39 potential splicing
SNPs which can affect the alternative splicing process.
Our analysis gives an overview on the SNP landscape of
NYBR1 and now provides the basis to further study the
association of SNPs and the molecular breast cancer
subtypes “Her2”, “Luminal A/B” and “Triple negative” as
well as clinical data, such as treatment response, relapse
rate and overall survival.
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